Tarlatamab combined with PD-L1 inhibitors shows potential in improving survival for ES-SCLC, with a median OS of 25.3 months. The combination may bypass tumor immune evasion by redirecting T-cells to ...
The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma (NPC) in adults. No trade name was indicated for the drug. The first ...
MedPage Today on MSN
PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma
First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial in second-line renal cell carcinoma (RSS). Image credit: Kateryna Kon ...
Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 Incyte (Nasdaq:INCY) today announced that ...
SEATTLE, WASHINGTON / ACCESS Newswire / May 8, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback